The present invention relates to a crystalline form of bictegravir sodium and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising said crystalline form of bictegravir sodium, preferably in a predetermined and/or effective amount, at least one pharmaceutically acceptable excipient and optionally one or more additional antiviral agent(s). The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prophylaxis of HIV-1 infections.
